Clinical Trials Logo

Testicular Germ Cell Tumor clinical trials

View clinical trials related to Testicular Germ Cell Tumor.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05063760 Active, not recruiting - Clinical trials for Testicular Germ Cell Tumor

Exercise in Testicular Germ Cell Cancer Survivors

ExCell
Start date: January 15, 2020
Phase: N/A
Study type: Interventional

Regular exercise is effective in prevention & treatment of chronic diseases. Exercise can reduce late toxicity of chemotherapy, commonly found in cancer survivors, which is yet to be translated into clinical practice. Mechanisms of exercise benefits in oncologic patients are far from being elucidated, and include increase in muscle mass, reduction of fat mass, systemic inflammation and cardiometabolic risk. Synchronization of exercise adaptive response is, to an extent, mediated by bioactive molecules released from muscle, with anti-inflammatory & tumor-suppressing properties. Muscle satellite cells are a source of regeneration, muscle structural integrity & functional capacity. Phenotypes of muscle cells, such as secretory profile, lipid & glucose metabolism, mirror clinical phenotypes of the donor. Importantly, muscle cells' metabolism in vitro can be modulated by 8-12 week training in vivo. Epigenetic mechanisms regulating muscle & systemic metabolism in cancer survivors are not yet understood.

NCT ID: NCT03426865 Active, not recruiting - Clinical trials for Testicular Germ Cell Tumor

Role of Axumin PET Scan in Germ Cell Tumor

TESTPET
Start date: March 1, 2018
Phase:
Study type: Observational

Investigators will use Axumin PET/CT to help with the imaging modalities to determine the presence of occult retroperitoneal disease.

NCT ID: NCT00104676 Active, not recruiting - Clinical trials for Testicular Germ Cell Tumor

Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors

Start date: November 26, 2003
Phase: Phase 3
Study type: Interventional

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This randomized phase III trial is comparing two different combination chemotherapy regimens to see how well they work in treating patients with stage II or stage III non-seminomatous germ cell tumors.

NCT ID: NCT00004219 Active, not recruiting - Clinical trials for Testicular Germ Cell Tumor

Lerisetron Compared With Granisetron in Preventing Nausea and Vomiting in Men Being Treated With Radiation Therapy for Stage I Seminoma

Start date: n/a
Phase: Phase 3
Study type: Interventional

RATIONALE: Antiemetic drugs may help to reduce or prevent nausea and vomiting in patients treated with radiation therapy. It is not yet known whether lerisetron is more effective than granisetron in preventing nausea and vomiting. PURPOSE: Randomized phase III trial to compare the effectiveness of lerisetron with that of granisetron in preventing nausea and vomiting in men who are being treated with radiation therapy for stage I seminoma.

NCT ID: NCT00003643 Active, not recruiting - Clinical trials for Testicular Germ Cell Tumor

Combination Chemotherapy in Treating Men With Germ Cell Cancer

Start date: October 1998
Phase: Phase 2/Phase 3
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which regimen of combination chemotherapy may be more effective for germ cell cancer. PURPOSE: This randomized phase II/III trial is studying two different regimens of combination chemotherapy and comparing how well they work in treating men with germ cell cancer.